Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Late-Stroke patients: clot removal may work even days later

NCT ID NCT06101667

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests whether a procedure to reopen a major blocked artery in the brain can help people who had a severe stroke 24 to 72 hours earlier. About 224 participants will either get the procedure plus standard care or standard care alone. The goal is to see if the procedure improves recovery and reduces disability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

224 people

The number who actually took part.

Started

Nov 2023

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age≥18 years 2. Acute basilar artery occlusion confirmed by CTA, MRA, or DSA 3. Pre-stroke mRS of 0-2 4. NIHSS score ≥ 10 before randomization 5. Time interval from symptom onset (or last known well) to randomization within 24-72 hours 6. Diffusion-weighted imaging(DWI)-based pc-ASPECTS ≥ 6 and Pons-Midbrain Index (PMI) ≤3 7. Time from completion of DWI imaging to randomization is ≤3 hours 8. Each patient or their legal representative must provide written informed consent before enrolment Exclusion Criteria: 1. Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization 2. Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging 3. CT or MRI evidence of intracranial tumor (except small meningioma and cerebral aneurysm \< 3mm in diameter) 4. Known or highly suspected chronic occlusion of basilar artery 5. History of contraindication for contrast medium (except mild rash) 6. Current pregnant or breast-feeding 7. Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up 8. Life expectancy is less than 3 months 9. Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months. 10. Any other condition (in the opinion of the site investigator) that inappropriate to participate this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Tiantan Hospital

    Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.